Table F9Dementia—active controlled trials versus conventionals

ConventionalAtypicals
Adverse EventsDrug# of studies# adverse eventssample size# adverse eventssample sizePooled OR95% CI
Appetite or Weight/DecreaseOlanzapine13284301.28(0.19, 9.61)
Appetite or Weight/IncreaseOlanzapine319221282231.53(0.79, 3.03)
Appetite or Weight/IncreaseRisperidone1020020NCNC
CardiovascularOlanzapine1217361733.06(0.54, 31.45)
Cardiovascular/BP/DecreaseOlanzapine17202200.11(0.00, 1.01)
Cardiovascular/BP/DecreaseRisperidone17204200.47(0.08, 2.36)
Cardiovascular/BP/IncreaseQuetiapine11111111.00(0.01, 86.25)
Cardiovascular/RhythmOlanzapine26483500.46(0.07, 2.29)
Cardiovascular/RhythmRisperidone15202200.17(0.00, 1.80)
Constitutional/Fever or InfectionOlanzapine1317301730.00(0.00, 2.41)
DeathOlanzapine1617341730.66(0.13, 2.84)
DermatologicOlanzapine112287300.41(0.11, 1.43)
Endocrine/DiabetesOlanzapine2219331931.50(0.17, 18.14)
Endocrine/DiabetesRisperidone1020020NCNC
GastrointestinalOlanzapine364221242230.14(0.06, 0.30)
GastrointestinalQuetiapine1011111+Inf(0.03, Inf+ )
GastrointestinalRisperidone210496490.43(0.10, 1.65)
HEENT/Decreased SalivationOlanzapine210483500.25(0.04, 1.05)
HEENT/Decreased SalivationRisperidone16200200.00(0.00, 0.72)
HEENT/Increased SalivationOlanzapine17284300.47(0.09, 2.14)
InfectionsQuetiapine11110110.00(0.00, 39.00)
NeuroOlanzapine2204815500.55(0.20, 1.47)
NeuroRisperidone13200200.00(0.00, 2.34)
Neuro/FatigueOlanzapine2224818500.42(0.11, 1.49)
Neuro/FatigueRisperidone1020220+Inf(0.03, Inf+ )
Neuro/Movement DisorderOlanzapine1182819300.96(0.29, 3.20)
Neuro/Movement Disorder/AkathisiaOlanzapine26485500.57(0.10, 2.76)
Neuro/Movement Disorder/AkathisiaRisperidone1020020NCNC
Neuro/Movement Disorder/EPSOlanzapine2244817500.37(0.12, 1.10)
Neuro/Movement Disorder/EPSQuetiapine12110110.00(0.00, 5.24)
Neuro/Movement Disorder/EPSRisperidone14202200.23(0.00, 2.65)
Neuro/SedationOlanzapine367221642230.90(0.57, 1.42)
Neuro/SedationRisperidone325163181640.68(0.33, 1.36)
Neuro/SensoryOlanzapine12282300.93(0.06, 13.69)
Psychiatric/ApathyOlanzapine1162810300.38(0.11, 1.23)
Psychiatric/CognitiveOlanzapine149285330NCNC
Psychiatric/DepressionOlanzapine1202817300.53(0.15, 1.77)
Psychiatric/IrritabilityOlanzapine1232824300.87(0.18, 3.97)
Psychiatric/SexualOlanzapine1020020NCNC
Psychiatric/SexualRisperidone1020120NCNC
Psychiatric/Sexual/Decreased FunctionOlanzapine13284301.28(0.19, 9.61)
Psychiatric/SleepOlanzapine223483450NCNC
Psychiatric/SleepRisperidone1020120NCNC
SweatingOlanzapine14285301.20(0.23, 6.79)
TraumaOlanzapine11317311730.07(0.00, 0.49)
UrinaryOlanzapine212201122030.90(0.29, 2.80)
UrinaryRisperidone1029129+Inf(0.03, Inf+ )

CI = confidence interval; HEENT = head, eye, ear, nose, and throat; NC = not calculated; OR = odds ratio

From: Appendix F, Adverse Events Analyses

Cover of Off-Label Use of Atypical Antipsychotics: An Update
Off-Label Use of Atypical Antipsychotics: An Update [Internet].
Comparative Effectiveness Reviews, No. 43.
Maglione M, Maher AR, Hu J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.